Key facts
- Notable investors include Seoul National University Technology Holdings.
- Status: Privately Held (backing).
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for AImmuneLink
- ·The full record, as it builds
Funding rounds
No funding rounds for AImmuneLink are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AImmuneLink
Operator of a healthcare company intended to specialize in immune medicine and personalized health management based on immunome data analysis. The company does immunity precision medicine service, single-cell analysis, immune response analysis, and proteome analysis, enabling customers to get accurate immunity testing services.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2024
- Website
- aimmunelink.com/
- Ownership
- Privately Held (backing)
AImmuneLink doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AImmuneLink shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AImmuneLink in its N-PORT filings yet. We sweep new filings monthly.